Molecular Mechanisms and Therapeutic Approaches in Friedreich Ataxia

Friedreich ataxia is an autosomal recessive neuro-cardiac disorder caused by a GAA trinucleotide repeat expansion in the FXN gene, leading to reduced synthesis of frataxin. Frataxin deficiency impairs iron-sulfur cluster assembly, compromising mitochondrial respiratory chain complexes and triggering oxidative stress. Neuronal loss in dorsal root ganglia and cerebellar pathways drives progressive ataxia, while cardiomyocyte iron accumulation and mitochondrial dysfunction underlie hypertrophic cardiomyopathy. Epigenetic silencing at the FXN locus and actin remodelling further exacerbate antioxidant pathway defects. Therapeutic strategies under investigation aim to restore frataxin levels or counter downstream consequences. Gene therapy and genome editing seek to correct the expanded GAA repeats or deliver functional FXN. Small molecules such as histone deacetylase inhibitors and nicotinamide aim to reverse heterochromatinisation and upregulate FXN transcription. Antioxidant approaches focus on activating the Nrf2 pathway or supplying radical scavengers to buffer reactive oxygen species, while emerging compounds target mitochondrial bioenergetics and lipid peroxidation. Cellular models—including patient-derived induced pluripotent stem cells—are widely used for mechanistic studies and high-throughput screening. Digital biomarkers derived from wearable sensors and machine-learning algorithms are being developed to track disease progression more precisely. Together, these approaches span from fundamental insights into iron-sulfur cluster biology and mitochondrial translation to translational platforms poised to accelerate clinical evaluation.

Research from Nature Portfolio

Recent studies have leveraged wearable motion-capture technology combined with machine learning to derive digital behavioural features that predict clinical ataxia scores and FXN gene expression up to nine months in advance. This approach outperforms traditional scales in precision and offers scalable biomarkers to shorten trial duration. In parallel, chemogenetic mouse models expressing D-amino acid oxidase in neurons and endothelium have demonstrated that targeted neurovascular oxidative stress is sufficient to induce sensory ataxia and cardiac hypertrophy mirroring Friedreich ataxia. These models provide mechanistic insight into how mitochondrial dysfunction and hydrogen peroxide production in specific cell types drive the dual neurological and cardiac pathology, offering a platform for testing antioxidative and mitochondrial-protective therapies.

Molecular Mechanisms and Therapeutic Approaches in Friedreich Ataxia publication trend

The graph below shows the total number of articles in molecular mechanisms and therapeutic approaches in friedreich ataxia across all publications each year (not limited to Nature Index journals).

Technical terms

Frataxin: A mitochondrial protein essential for iron-sulfur cluster biogenesis; its deficiency underlies Friedreich ataxia.

GAA trinucleotide repeat expansion: A pathogenic increase in the number of GAA repeats within the FXN gene intron that silences frataxin expression.

Iron-sulfur cluster: Cofactors consisting of iron and sulfur atoms that are required for electron transfer in mitochondrial respiratory complexes.

Induced pluripotent stem cells (iPSCs): Somatic cells reprogrammed to a pluripotent state, used to model patient-specific disease mechanisms in vitro.

Oxidative stress: Cellular damage resulting from an imbalance between reactive oxygen species production and antioxidant defences.

Nrf2: A transcription factor that regulates the expression of antioxidant and cytoprotective genes.

Digital biomarker: Objective, quantifiable data collected by digital devices to track physiological or behavioural states.

Mitoribosome: The mitochondrial ribosomal complex responsible for translating mitochondrially encoded proteins essential for oxidative phosphorylation.

References

1. A wearable motion capture suit and machine learning predict disease progression in Friedreich’s ataxia. Nature Medicine (2023).
2. Sensory ataxia and cardiac hypertrophy caused by neurovascular oxidative stress in chemogenetic transgenic mouse lines. Nature Communications (2023).
3. Patient-derived iPSC models of Friedreich ataxia: a new frontier for understanding disease mechanisms and therapeutic application. Translational Neurodegeneration (2023).
4. METTL17 is an Fe-S cluster checkpoint for mitochondrial translation. Molecular Cell (2024).
5. Epigenetic and neurological effects and safety of high-dose nicotinamide in patients with Friedreich's ataxia: an exploratory, open-label, dose-escalation study. The Lancet (2014).